Branded Pharmaceuticals
Daring to Challenge
Chemiphar is committed to being an innovative pharmaceutical R&D company, with researchers who have the passion to create pharmaceuticals with increased value for patients.
At the early stage of product development, we license out our compounds to specialized venture companies overseas. This allows us to avoid the risks accompanying development-related financial burdens, and speeds up product commercialization.
While Chemiphar has a history of developing new pharmaceuticals in the area of analgesics and urology, we are expanding our horizons in other areas.
Bone Disease
By focusing on cathepsin, the group of enzymes involved in bone loss and formation, we are developing bone disease therapy for such conditions as osteoporosis, rheumatoid arthritis and bone metastases.
In 2005, Chemiphar licensed out NC-2300, a compound for bone diseases, to Velcura Therapeutics, Inc., a U.S. bio-venture company. In cooperation with Velcura, the compound is undergoing development in the United States. In February 2008, Velcura started phase I clinical trials.
News release (August 2005)
Nippon Chemiphar reaches licensing agreement with Velcura Therapeutics, Inc. (pdf, 101KB)
PPAR Receptor Agonists
We focus on PPAR receptors that relate to life-style diseases, and try to create innovative pharmaceuticals that change therapies. Together with Cerenis Therapeutics, SA, based in Europe and the United States, we are developing some candidate compounds overseas.
News release (August 2005)
Nippon Chemiphar licenses R&D venture to develop PPAR delta agonist-based arteriosclerosis therapies (pdf, 67.7KB)
Hyperuricemia
It appears probable that the level of uric acid in the bloodstream will be found to be a key factor in determining the likely onset of metabolic syndrome. Chemiphar is in the process of developing a new agent for hyperuricemia.
Analgesics
Chemiphar's Soleton Tablet 80 (zaltoprofen), a non-steroidal anti-inflammatory drug (NSAID), reflects our R&D focus on new analgesics.
